Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:

• William Blair 46^th Annual Growth Stock Conference on Tuesday, June 2^nd, at 8:00 a.m. PT / 11:00 a.m. ET.
• 2026 Jefferies Global Healthcare Conference on Wednesday, June 3^rd, at 8:40 a.m. PT / 11:40 a.m. ET.
  
  

Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY^® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 as an ophthalmic gel for the potential treatment of ocular rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, both of which are in Phase 2.

Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
[email protected]

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
[email protected]

You May Also Be Interested In

• Robinhood Announces Pricing of Private Offering of $2.0 Billion of Convertible Senior Notes Due 2029
• Carol Anne Mills Expands Video First Real Estate Marketing Program Following Multiple South Bay Home Sales Above Asking Price
• Annual General Meeting of Shareholders to Be Held on September 9, 2026 and Adoption of Advance Notice By-Law